Llwytho...
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations. Drug-induced pneumonitis is known to occur with osimertinib. In case of severe pneu...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Adv Med Oncol |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8202262/ https://ncbi.nlm.nih.gov/pubmed/34178120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211018028 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|